Explore Exelixis' strong Q1 2025 performance, with growth in CABOMETYX, expanded financial guidance, and progress in oncology innovation.

Yields on the 10-year are rising amid renewed risk sentiment from U.S.-China tariff relief, testing crypto’s resilience as ...